Laboratory of Experimental Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hepatology. 2010 Apr;51(4):1401-9. doi: 10.1002/hep.23488.
Human hepatocellular carcinoma (HCC) is a heterogeneous disease of distinct clinical subgroups. A principal source of tumor heterogeneity may be cell type of origin, which in liver includes hepatocyte or adult stem/progenitor cells. To address this issue, we investigated the molecular mechanisms underlying the fate of the enzyme-altered preneoplastic lesions in the resistant hepatocyte (RH) model. Sixty samples classified as focal lesions, adenoma, and early and advanced HCCs were microdissected after morphological and immunohistochemical evaluation and subjected to global gene expression profiling. The analysis of progression of the persistent glutathione S-transferase (GSTP)(+) focal lesions to fully developed HCC showed that approximately 50% of persistent nodules and all HCCs expressed cytokeratin 19 (CK19), whereas 14% of remodeling nodules were CK19(+). Unsupervised hierarchical clustering of the expression profiles also grouped the samples according to CK19 expression. Furthermore, supervised analysis using the differentially expressed genes in each cluster combined with gene connectivity tools identified 1308 unique genes and a predominance of the AP-1/JUN network in the CK19(+) lesions. In contrast, the CK19-negative cluster exhibited only limited molecular changes (156 differentially expressed genes versus normal liver) consistent with remodeling toward differentiated phenotype. Finally, comparative functional genomics showed a stringent clustering of CK19(+) early lesions and advanced HCCs with human HCCs characterized by poor prognosis. Furthermore, the CK19-associated gene expression signature accurately predicted patient survival (P < 0.009) and tumor recurrence (P < 0.006).
Our data establish CK19 as a prognostic marker of early neoplastic lesions and strongly suggest the progenitor derivation of HCC in the rat RH model. The capacity of CK19-associated gene signatures to stratify HCC patients according to clinical prognosis indicates the usefulness of the RH model for studies of stem/progenitor-derived HCC.
人类肝细胞癌(HCC)是一种具有不同临床亚组的异质性疾病。肿瘤异质性的主要来源可能是细胞起源类型,在肝脏中包括肝细胞或成体干细胞/祖细胞。为了解决这个问题,我们研究了在抗性肝细胞(RH)模型中改变酶的癌前病变的命运的分子机制。60 个样本经过形态学和免疫组织化学评估后被分类为局灶性病变、腺瘤、早期和晚期 HCC,并进行了全基因表达谱分析。对持续谷胱甘肽 S-转移酶(GSTP)(+)局灶性病变向完全发育的 HCC 进展的分析表明,大约 50%的持续性结节和所有 HCC 都表达细胞角蛋白 19(CK19),而 14%的重塑结节为 CK19(+)。表达谱的无监督层次聚类也根据 CK19 表达将样本分组。此外,使用每个簇中差异表达的基因进行的有监督分析,并结合基因连接工具,确定了 1308 个独特的基因,以及 CK19(+)病变中 AP-1/JUN 网络的优势。相比之下,CK19 阴性簇仅表现出有限的分子变化(156 个差异表达基因与正常肝脏相比),这与向分化表型重塑一致。最后,比较功能基因组学显示,CK19(+)早期病变和晚期 HCC 与具有不良预后的人类 HCC 严格聚类。此外,CK19 相关的基因表达谱准确地预测了患者的生存(P < 0.009)和肿瘤复发(P < 0.006)。
我们的数据确立了 CK19 作为早期肿瘤病变的预后标志物,并强烈表明大鼠 RH 模型中的 HCC 来源于祖细胞。CK19 相关基因特征根据临床预后对 HCC 患者进行分层的能力表明 RH 模型在研究干细胞/祖细胞衍生的 HCC 中的有用性。